期刊文献+

琥珀酸索利那新和酒石酸托特罗定治疗前列腺电切术后OAB疗效比较

下载PDF
导出
摘要 目的评价经尿道前列腺切除术后早期使用索利那新和托特罗定对早期膀胱过度活动症症状的临床疗效和不良反应发生率的差异。方法选择本院36例尿道前列腺切除术后住院患者,随机将36例患者分为实验组与对照组,实验组于手术当日起即口服索利那新5mg/次,1次/d,至拔除尿管后3d停药。对照组手术当日起即口服托特罗定,2mg/次,2次/d,至拔除尿管后3d停药。结果实验组膀胱痉挛每日发作次数、持续时间、每日排尿次数及急迫性尿失禁发作次数均低于对照组(P<0.01),且不良反应发生率低于对照组。结论索利那新对于预防和治疗TURP术后早期膀胱过度活动症效果优于托特罗定,且不良反应发生率显著低于托特罗定。
作者 胡建渝
出处 《中国医学创新》 CAS 2012年第7期45-46,共2页 Medical Innovation of China
  • 相关文献

参考文献7

二级参考文献16

  • 1Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function, report from the standardisaton subcommittee of the International Continence Society. Neurourol Urodyn, 2002, 21: 167-178.
  • 2Rovner ES, Wein AJ. Incidence and prevalence of overactive bladder. Curr Urol Rep, 2002, 3:434- 438.
  • 3Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int, 2006, 97: 96-100.
  • 4Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int, 2007, 100: 987-1006.
  • 5Ikeda K, Kobayashi S, Suzuki M, et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. N-S Arch Pharmacol, 2002, 366: 97-103.
  • 6Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmaeol, 2004, 492:243- 250.
  • 7Kobayashi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci, 2004, 74: 843-853.
  • 8Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol, 2004, 44:1023- 1033.
  • 9Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int, 2004, 93: 71-77.
  • 10宋波,杨勇,廖利民.膀胱过度活动症诊断治疗指南∥那彦群.中国泌尿外科疾病诊断治疗指南.北京:人民卫生出版社,2007:330.

共引文献211

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部